Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis

Wankhede, Durgesh; Grover, Sandeep; Hofman, Paul

doi:10.1016/j.vaccine.2023.01.072

Cited by 12 publications

(14 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…A total of 1,596 publications were identified in the literature search. After applying the eligibility criteria, 102 studies remained, forming the evidentiary basis for the guideline recommendations: 24 systematic reviews, 11, 14 RCTs, 6,[44][45][46][47][48][49][50][51][52][53][54][55][56] and 64 nonrandomized studies. [85][86][87][88][89][90][91][92][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][110][111][112][113][114][115][116][117][118][119]…”

Section: Characteristics Of Studies Identified In the Literature Searchmentioning

confidence: 99%

“…Humoral responses are only minimally diminished in patients with solid tumors who are receiving immune checkpoint inhibitors (ICIs) or targeted therapy. 11 Seroconversion rates are heterogeneous and overall lower among patients with hematologic cancer than patients with solid tumors. 22,30,31,34,37,40 In a 2022 meta-analysis, seroconversion after two vaccine doses was 95% among patients with solid tumors, 64% among patients with hematologic cancers, and 42% in patients with chronic lymphocytic leukemia (CLL).…”

Section: Literature Review and Analysismentioning

confidence: 99%

“…5,10 Conversely, nonlive vaccines are generally considered safe, but their ability to produce immune responses may differ depending on the net state of immunosuppression. 5,11,12 To improve vaccination rates among patients with cancer, ASCO has engaged with the Centers for Disease Control and Prevention (CDC), Council of Medical Specialty Societies, and other specialty societies in a 5-year cooperative agreement. 13 Along with supporting the development of this guideline, the cooperative agreement includes efforts in provider education, patient education, and quality improvement.…”

Section: Introductionmentioning

confidence: 99%

“…5,10 Conversely, nonlive vaccines are generally considered safe, but their ability to produce immune responses may differ depending on the net state of immunosuppression. 5,11,12…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Vaccination of Adults With Cancer: ASCO Guideline

Kamboj,

Bohlke,

Baptiste

et al. 2024

JCO

View full text Add to dashboard Cite

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE To guide the vaccination of adults with solid tumors or hematologic malignancies. METHODS A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and nonrandomized studies on the efficacy and safety of vaccines used by adults with cancer or their household contacts. This review builds on a 2013 guideline by the Infectious Disease Society of America. PubMed and the Cochrane Library were searched from January 1, 2013, to February 16, 2023. ASCO convened an Expert Panel to review the evidence and formulate recommendations. RESULTS A total of 102 publications were included in the systematic review: 24 systematic reviews, 14 RCTs, and 64 nonrandomized studies. The largest body of evidence addressed COVID-19 vaccines. RECOMMENDATIONS The goal of vaccination is to limit the severity of infection and prevent infection where feasible. Optimizing vaccination status should be considered a key element in the care of patients with cancer. This approach includes the documentation of vaccination status at the time of the first patient visit; timely provision of recommended vaccines; and appropriate revaccination after hematopoietic stem-cell transplantation, chimeric antigen receptor T-cell therapy, or B-cell–depleting therapy. Active interaction and coordination among healthcare providers, including primary care practitioners, pharmacists, and nursing team members, are needed. Vaccination of household contacts will enhance protection for patients with cancer. Some vaccination and revaccination plans for patients with cancer may be affected by the underlying immune status and the anticancer therapy received. As a result, vaccine strategies may differ from the vaccine recommendations for the general healthy adult population vaccine. Additional information is available at www.asco.org/supportive-care-guidelines .

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Characteristics Of Studies Identified In the Literature Searchmentioning

confidence: 99%

Section: Literature Review and Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…5,10 Conversely, nonlive vaccines are generally considered safe, but their ability to produce immune responses may differ depending on the net state of immunosuppression. 5,11,12…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Vaccination of Adults With Cancer: ASCO Guideline

Kamboj,

Bohlke,

Baptiste

et al. 2024

JCO

View full text Add to dashboard Cite

show abstract

Vaccination anti-infectieuse : pour qui ? Quand ? Comment ?

Lachâtre,

Murris-Espin,

Mazières

2023

Revue des Maladies Respiratoires Actualités

View full text Add to dashboard Cite

SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors

Yang

2023

Cell Death Dis

View full text Add to dashboard Cite

Cancer patients are susceptible to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Different antitumor treatments have attracted wide attention in the context of coronavirus disease 2019 (COVID-19), especially immune checkpoint inhibitors (ICIs) that have revolutionized oncology changes. It may also have protective and therapeutic roles in viral infections. In this article, we collected 26 cases of SARS-CoV-2 infection during ICIs therapy and 13 related to COVID-19 vaccination from Pubmed, EMBASE, and Wed of Science. Of these 26 cases, 19 (73.1%) presented mild cases and 7 (26.9%) were severe cases. Melanoma (47.4%) was a common cancer type in mild cases and lung cancer (71.4%) in severe cases (P = 0.016). The results showed that their clinical outcomes varied widely. Although there are similarities between the immune checkpoint pathway and COVID-19 immunogenicity, ICIs therapy overactivated T cells, which often leads to immune-related adverse events. In fact, the COVID-19 vaccine has been shown to be safe and effective in patients treated with ICIs. In this review, we report the vital clinical observations of SARS-CoV-2 infection or vaccination in cancer patients treated with ICIs and explore the potential interaction between them.

show abstract

Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis

Cited by 12 publications

References 63 publications

Vaccination of Adults With Cancer: ASCO Guideline

Vaccination of Adults With Cancer: ASCO Guideline

Vaccination anti-infectieuse : pour qui ? Quand ? Comment ?

SARS-CoV-2 infection and COVID-19 vaccination in cancer patients undergoing immune checkpoint inhibitors

Contact Info

Product

Resources

About